<DOC>
	<DOCNO>NCT02150928</DOCNO>
	<brief_summary>The purpose study evaluate serum asparaginase activity subject age 18 &lt; 40 year ALL LBL develop hypersensitivity native E. coli asparaginase pegaspargase .</brief_summary>
	<brief_title>An Open-Label , Single-Arm , Multicenter Pharmacokinetic Study Intramuscular Erwinaze® ( Asparaginase Erwinia Chrysanthemi ) /Erwinase® ( Crisantaspase )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>1 . Have diagnosis ALL LBL 2 . Be 18 &lt; 40 year age time enrollment 3 . Have document ≥ Grade 2 clinical hypersensitivity reaction native E. coli asparaginase ( e.g. , Elspar Kidrolase ) pegaspargase ( Oncaspar ) 4 . Have follow asparaginase dose remain treatment plan : At least two ( 2 ) consecutive week native E. coli asparaginase treatment OR At least one ( 1 ) dose pegaspargase ( Oncaspar ) 5 . Have direct bilirubin ≤ Grade 2 ( &lt; 3.0 mg/dL [ 52 µmol/L ] ) 6 . Have amylase lipase within normal limit ( per institutional standard ) 7 . Have serum asparaginase activity detectable limit screen prior first dose study drug ( Erwinaze ) 8 . Consent use medically acceptable method contraception throughout entire study period 4 week study complete . Medically acceptable method contraception may use subject and/or partner include abstinence , birth control pills patch , diaphragm spermicide , condom vaginal spermicide , surgical sterilization , postmenopausal , vasectomy ( &gt; 6 month prior baseline ) , progestin implant injection . 9 . Have sign inform consent 1 . Prior history ≥ Grade 3 pancreatitis 2 . Prior history major thrombotic event assess investigator , subject history asparaginaseassociated serious hemorrhagic thrombotic event require prolonged anticoagulation therapy agent heparin 3 . Prior treatment Erwinaze 4 . Pregnant lactate female subject female subject childbearing potential willing use adequate method birth control ( list ) duration study 5 . Subjects history human immunodeficiency virus ( HIV ) hepatitis . 6 . Any condition would cause risk ( investigator 's judgment ) subject participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>